Shots:

• The companies collaborated to develop a blood-based CDx test to identify patients expressing DGM1 & respond to Denovo’s DB102 for treatment of DLBCL
• Qiagen will develop a diagnostic assay to identify the DGM1 in DLBCL patients & develop a real-time qualitative PCR companion diagnostic for the QIAGEN Rotor-Gene Q MDx instrument and apply for PMA with the US FDA
• DB102 and the DGM1 marker are currently in a P-III (ENGINE) trial on newly diagnosed, high-risk DLBCL patients. Additionally, Qiagen is working under collaboration agreements with 25+ companies to develop and commercialize CDx tests & strengthen the precision therapies for patients benefit

Ref: Businesswire | Image: Qiagen